Our top pick for
Building a portfolio
Edesa Biotech, Inc is a biotechnology business based in the US. Edesa Biotech shares (EDSA) are listed on the NASDAQ and all prices are listed in US Dollars. Edesa Biotech employs 12 staff and has a trailing 12-month revenue of around USD$328,801.
|Latest market close||USD$5.2|
|52-week range||USD$1.58 - USD$10.15|
|50-day moving average||USD$5.1109|
|200-day moving average||USD$6.2387|
|Wall St. target price||USD$15.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-5.794|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||5.05%|
|1 month (2020-12-24)||8.56%|
|3 months (2020-10-22)||-19.50%|
|6 months (2020-07-22)||-2.44%|
|1 year (2020-01-22)||54.81%|
|2 years (2019-01-22)||352.17%|
|3 years (2018-01-22)||471.18%|
|5 years (2016-01-22)||5.47|
|Gross profit TTM||USD$311,200|
|Return on assets TTM||-48.55%|
|Return on equity TTM||-88.61%|
|Market capitalisation||USD$50 million|
TTM: trailing 12 months
There are currently 24,632 Edesa Biotech shares held short by investors – that's known as Edesa Biotech's "short interest". This figure is 13.7% down from 28,530 last month.
There are a few different ways that this level of interest in shorting Edesa Biotech shares can be evaluated.
Edesa Biotech's "short interest ratio" (SIR) is the quantity of Edesa Biotech shares currently shorted divided by the average quantity of Edesa Biotech shares traded daily (recently around 107095.65217391). Edesa Biotech's SIR currently stands at 0.23. In other words for every 100,000 Edesa Biotech shares traded daily on the market, roughly 230 shares are currently held short.
However Edesa Biotech's short interest can also be evaluated against the total number of Edesa Biotech shares, or, against the total number of tradable Edesa Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Edesa Biotech's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Edesa Biotech shares in existence, roughly 0 shares are currently held short) or 0.0048% of the tradable shares (for every 100,000 tradable Edesa Biotech shares, roughly 5 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Edesa Biotech.
Find out more about how you can short Edesa Biotech stock.
We're not expecting Edesa Biotech to pay a dividend over the next 12 months.
Edesa Biotech's shares were split on a 1:6 basis on 10 June 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Edesa Biotech shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Edesa Biotech shares which in turn could have impacted Edesa Biotech's share price.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.